Metachronous pancreatic metastases from renal cell carcinoma: is there a place of Active-Surveillance before deferred deliberately Molecular Target Agent?

World Journal of Surgical Oncology

Case Report

Hassan Seddik¹  Hassan Errihani²  Fahd Benani³  Mohamed Ichou³  Khaoula Slimani³  Adil Debbagh³  Yassir Sbitti⁴  Mohamed Mahi⁵  Abdelmounaim Aitali⁵  Abderrahmane Albouzidi⁶  Mohamed Tarchouli⁷ 

[1] Department of Gastroenterology, University Military Hospital, 10000, Rabat, Morocco;Department of Medical Oncology, National Institute of Oncology, 10000, Rabat, Morocco;Department of Medical Oncology, University Military Hospital, 10000, Rabat, Morocco;Department of Medical Oncology, University Military Hospital, 10000, Rabat, Morocco;Department Medical Oncology, Teaching University Military Hospital and Faculty of Medicine and Pharmacy of Fes, Hay Ryad, 10000, Rabat, Morocco;Department of Pathology, University Military Hospital of Instruction, 10000, Rabat, Morocco;Department of Radiology, University Military Hospital of Instruction, 10000, Rabat, Morocco;Department of Surgery, University Military Hospital of Instruction, 10000, Rabat, Morocco;

关键词: Renal cell carcinoma;    Pancreatic metastases;    Active surveillance;    Molecular target therapy;   

DOI  :  10.1186/s12957-016-0939-9

 received in 2016-04-13, accepted in 2016-07-08,  发布年份 2016

来源: Springer

【 摘 要 】

BackgroundMetastatic renal cell cancer is a heterogeneous disease due to its diverse morphological features, the prognostic categories based on clinical criteria. Sometimes indolent course without any significant symptoms can be differentiated before the introduction of novel targeted agents. This observation led to interest in a strategy of deferring systemic therapy in the era of effective systemic therapies.Case presentationWe report of a 78-year-old Moroccan man with pancreatic metastasis from renal cell carcinoma which occurred 14 years from right nephrectomy. Indolent disease based on body computed tomography imaging with 4 years follow-up was recognized. Active surveillance with deferred antiangiogenic multikinase inhibitor at disease progression was proposed. Nowadays, the patient is under oncological follow-up, he is in a good state of health, and he is disease-free for 48 months from the diagnosis of the tumor and for 20 months from the start of the treatment with SunitinibConclusionsActive surveillance before target therapy may be a suitable approach to ensure long progression-free survival with minimal side-effects and better quality of life in asymptomatic, low-volume, metastatic disease. Further prospective studies with biomarker validation are required to define the patients most likely to benefit from this approach.

【 授权许可】

CC BY   
© The Author(s). 2016